(Photo credit MIGUEL MEDINA/AFP/Getty Images)

Genzyme Jumps Into Rapidly Growing Business Of Genetic Medicines

Genzyme is spending $700 million dollars to buy a chunk of Alnylam Pharmaceuticals of Cambridge — a much smaller company that been moving rapidly toward commercializing treatments for rare genetic diseases.


boston skyline - thinkstock

Sanofi-Aventis Sees A Bright Future In Boston-Cambridge

Sanofi CEO Chris Viehbacher says research departments have been consolidated here to be near universities.


Harvard's Innovation Lab (Photo courtesy: Kyle Alspach, Boston Business Journal)

Business Headlines: Harvard’s Innovation Lab; More Foreign Students

Harvard University is stepping up its efforts to innovate.


Genzyme headquarters

How Genzyme Became Vulnerable To Sale

Analysts say Genzyme’s decision to manufacture a third drug at it’s Allston facility eventually led to its sale.


(AP Graphic

It’s A Done Deal For Genzyme

After nine months of denials, rejection, bickering and finally, discussion, French pharmaceutical company Sanofi-Aventis of Paris has signed a deal to buy Genzyme of Cambridge for $20.1 billion plus other milestone payments in the future.


Genzyme headquarters

Genzyme Sold To Sanofi-Aventis In $20 Billion Deal

Cambridge-based biotechnology company Genzyme is being bought by French drug maker Sanofi-Aventis for $20.1 billion, ending months of corporate haggling.



Before The Bell – Genzyme Sold

WBZ News Radio’s Bob Gough, in for Financial Editor Dave Caruso takes a look at the sale of Cambridge-based Genzyme.

WBZ NewsRadio 1030–02/16/2011

Genzyme headquarters

Genzyme Rejects Latest Sanofi Offer

Sanofi-Aventis extended its unsolicited $18.5 billion takeover offer for Cambridge biotech company Genzyme Corp. Monday.


(credit: AP)

Patrick Admin. Denies Asking Raytheon To Delay Layoff Announcement

Raytheon announced a series of layoffs Tuesday just days after Gov. Deval Patrick denied asking it to delay terminations until after the election.


Genzyme headquarters

Job Cuts Begin At Genzyme

Biotechnology company Genzyme is cutting 392 positions as it starts the first phase of a plan to eliminate 1,000 by the end of next year.